Aridis Pharmaceuticals Inc
NASDAQ:ARDS
Aridis Pharmaceuticals Inc
NASDAQ:ARDS
Price:
0.065 USD
Market Closed
Updated:
Apr 28, 2024
Section:
Relative Value
The Relative Value of one
ARDS
stock under the Base Case scenario is
3.577
USD.
Compared to the current market price of 0.065 USD,
Aridis Pharmaceuticals Inc
is
Undervalued by 98%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ARDS
Relative Value
Base Case
3.577
USD
Undervaluation 98%
Valuation Multiples
Multiples Across Competitors
ARDS Competitors Multiples
Aridis Pharmaceuticals Inc Competitors
Aridis Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Aridis Pharmaceuticals Inc
NASDAQ:ARDS
|
2.9m USD | 0.1 | -2.5 | -5 | -3.2 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
281.9B USD | 5.2 | 58.5 | 12.7 | 19.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
144.5B USD | 5.1 | 21.5 | 16.1 | 24.1 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
102.4B USD | 10.4 | 28.3 | 22.6 | 23.7 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
96.6B USD | 7.4 | 24.4 | 16.1 | 17.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
132B AUD | 6.1 | 34.9 | 21.2 | 26.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.5B USD | 3 | 14.4 | 7.9 | 10.2 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
41.2B USD | 6 | -8.7 | -9.2 | -7.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
30.3B USD | 3.1 | 26.1 | 14.2 | 17.6 | |
| KR |
|
Celltrion Inc
KRX:068270
|
36.6T KRW | 16.8 | 68.3 | 41.9 | 57.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
